Entropy Neurodynamics

Entropy Neurodynamics FCF Growth

The Year-over-Year Free Cash Flow Growth of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 56.84 %. In the previous year, Year-over-Year Free Cash Flow Growth was -31.72 % — a change of -279.19% (higher).

FCF Growth

56.84 %

YoY

-279.19%

Last updated:

Year-over-Year Free Cash Flow Growth of Entropy Neurodynamics is 2026 56.84 % . Year-over-Year Free Cash Flow Growth of Entropy Neurodynamics was 2025 -31.72 % . It decreases by -279.19% higher compared to the previous year.

The Entropy Neurodynamics FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-2,265.07 AUD
Jan 1, 2020
-170.41 AUD
Jan 1, 2021
-29.41 AUD
Jan 1, 2022
-2.17 AUD
Jan 1, 2023
58.58 AUD
Jan 1, 2024
-49.04 AUD
Jan 1, 2025
-31.72 AUD
Jan 1, 2026
56.84 AUD
The Entropy Neurodynamics FCF Growth history
YEARFCF GrowthYoY
56.84 %-279.19%
-31.72 %-35.32%
-49.04 %-183.72%
58.58 %-2,799.51%
-2.17 %-92.62%
-29.41 %-82.74%
-170.41 %-92.48%
-2,265.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Year-over-Year Free Cash Flow Growth of Entropy Neurodynamics is 56.84 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics